Mektovi (binimetinib) — United Healthcare
Succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST)
Preferred products
- imatinib mesylate (Gleevec)
Initial criteria
- Diagnosis of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST)
- Disease is one of the following: gross residual disease (R2 resection), unresectable primary disease, tumor rupture, progressive, recurrent, or metastatic
- Used in combination with imatinib mesylate (Gleevec)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Mektovi therapy
- Used in combination with imatinib mesylate (Gleevec)
Approval duration
12 months